Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhIL-15 and Mogamulizumab in Relapsed/Refractory ATLL and MF/SS
NCT04185220Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2020
- Primary completion
- Nov 2020
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of recombinant human interleukin-15 in adult T-cell leukemia-lymphoma (ATLL), mycosis fungoides (MF) and Sézary syndrome (SS) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 28 days and Number of Grade 1-4 Treatment Related Adverse Events up to 6 months. Started Feb 2020; status: completed.
02
Drugs
recombinant human interleukin-15
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT04185220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04185220.